Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine - PR Newswire

/PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology...

Trial is assessing safety and immunogenicity of intramuscular, live-attenuated influenza vaccine, CodaVax- H1N1, in healthy adults FARMINGDALE, N.Y., June 14, 2022 /PRNewswire/ -- Codagenix Inc., a … [+3471 chars]

full article...